SRSF2
SRSF2 (Serine/arginine-rich splicing factor 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Myelodysplastic syndromes / neoplasms and 3 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA. Interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. Binds to purine-rich RNA sequences, either 5'-AGSAGAGTA-3' (S=C or G) or 5'-GTTCGAGTA-3'. Can bind to beta-globin mRNA and commit it to the splicing pathway. Location: Nucleus; Nucleus, nucleoplasm; Nucleus speckle (UniProt). Locus 17q25.2 (HGNC).
- Myeloproliferative neoplasms: Open Targets association 0.83 with myeloproliferative neoplasm (MONDO_0020076)
- Leukaemia: Open Targets association 0.83 with leukaemia (MONDO_0005059)
- Myelodysplastic syndromes / neoplasms: Open Targets association 0.68 with myelodysplastic syndrome (MONDO_0018881); CIViC evidence names this disease
- Non-Hodgkin lymphoma: Open Targets association 0.51 with non-Hodgkin lymphoma (MONDO_0018908)
- Skin cancer: Open Targets association 0.50 with skin cancer (MONDO_0002898)
- Acute myeloid leukaemia: Open Targets association 0.79 with acute myeloid leukaemia (MONDO_0018874); CIViC evidence names this disease
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"SRSF2" OR ABSTRACT:"SRSF2" OR TITLE:"serine and arginine rich splicing factor 2" OR ABSTRACT:"serine and arginine rich splicing factor 2" OR TITLE:"Serine/arginine-rich splicing factor 2" OR ABSTRACT:"Serine/arginine-rich splicing factor 2" OR TITLE:"SC-35" OR ABSTRACT:"SC-35" OR TITLE:"SC35" OR ABSTRACT:"SC35" OR TITLE:"PR264" OR ABSTRACT:"PR264") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SRSF2, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/srsf2.json. Licence CC BY-NC 4.0.